These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 16149327)
1. Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis. Callaway JC; Brito GS; Neves ES J Psychoactive Drugs; 2005 Jun; 37(2):145-50. PubMed ID: 16149327 [TBL] [Abstract][Full Text] [Related]
2. Various alkaloid profiles in decoctions of Banisteriopsis caapi. Callaway JC J Psychoactive Drugs; 2005 Jun; 37(2):151-5. PubMed ID: 16149328 [TBL] [Abstract][Full Text] [Related]
3. Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay. Kummrow F; Maselli BS; Lanaro R; Costa JL; Umbuzeiro GA; Linardi A Environ Mol Mutagen; 2019 Apr; 60(3):269-276. PubMed ID: 30488498 [TBL] [Abstract][Full Text] [Related]
4. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127 [TBL] [Abstract][Full Text] [Related]
5. Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease. Wang YH; Samoylenko V; Tekwani BL; Khan IA; Miller LS; Chaurasiya ND; Rahman MM; Tripathi LM; Khan SI; Joshi VC; Wigger FT; Muhammad I J Ethnopharmacol; 2010 Apr; 128(3):662-71. PubMed ID: 20219660 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease. Katchborian-Neto A; Santos WT; Nicácio KJ; Corrêa JOA; Murgu M; Martins TMM; Gomes DA; Goes AM; Soares MG; Dias DF; Chagas-Paula DA; Paula ACC J Ethnopharmacol; 2020 Jun; 255():112743. PubMed ID: 32171895 [TBL] [Abstract][Full Text] [Related]
7. Biodiversity of β-Carboline Profile of Santos BWL; Oliveira RC; Sonsin-Oliveira J; Fagg CW; Barbosa JBF; Caldas ED Plants (Basel); 2020 Jul; 9(7):. PubMed ID: 32660098 [TBL] [Abstract][Full Text] [Related]
8. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context. Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972 [TBL] [Abstract][Full Text] [Related]
9. Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage. Pires AP; De Oliveira CD; Moura S; Dörr FA; Silva WA; Yonamine M Phytochem Anal; 2009; 20(2):149-53. PubMed ID: 19140116 [TBL] [Abstract][Full Text] [Related]
10. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312 [TBL] [Abstract][Full Text] [Related]
11. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Hamill J; Hallak J; Dursun SM; Baker G Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418 [TBL] [Abstract][Full Text] [Related]
12. The globalization of ayahuasca: harm reduction or benefit maximization? Tupper KW Int J Drug Policy; 2008 Aug; 19(4):297-303. PubMed ID: 18638702 [TBL] [Abstract][Full Text] [Related]
13. Identification of N,N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage. Gambelunghe C; Aroni K; Rossi R; Moretti L; Bacci M Biomed Chromatogr; 2008 Oct; 22(10):1056-9. PubMed ID: 18506697 [TBL] [Abstract][Full Text] [Related]
14. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. Santos RG; Landeira-Fernandez J; Strassman RJ; Motta V; Cruz AP J Ethnopharmacol; 2007 Jul; 112(3):507-13. PubMed ID: 17532158 [TBL] [Abstract][Full Text] [Related]
15. Chemical Composition of Traditional and Analog Ayahuasca. Kaasik H; Souza RCZ; Zandonadi FS; Tófoli LF; Sussulini A J Psychoactive Drugs; 2021; 53(1):65-75. PubMed ID: 32896230 [TBL] [Abstract][Full Text] [Related]
16. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015. Heise CW; Brooks DE J Med Toxicol; 2017 Sep; 13(3):245-248. PubMed ID: 27896660 [TBL] [Abstract][Full Text] [Related]
17. The complete organellar genomes of the entheogenic plant Varani AM; Silva SR; Lopes S; Barbosa JBF; Oliveira D; Corrêa MA; Moraes AP; Miranda VFO; Prosdocimi F PeerJ; 2022; 10():e14114. PubMed ID: 36275467 [No Abstract] [Full Text] [Related]
18. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease. Samoylenko V; Rahman MM; Tekwani BL; Tripathi LM; Wang YH; Khan SI; Khan IA; Miller LS; Joshi VC; Muhammad I J Ethnopharmacol; 2010 Feb; 127(2):357-67. PubMed ID: 19879939 [TBL] [Abstract][Full Text] [Related]
19. Determination of N,N-dimethyltryptamine in beverages consumed in religious practices by headspace solid-phase microextraction followed by gas chromatography ion trap mass spectrometry. Gaujac A; Dempster N; Navickiene S; Brandt SD; de Andrade JB Talanta; 2013 Mar; 106():394-8. PubMed ID: 23598143 [TBL] [Abstract][Full Text] [Related]